Date: 2012-09-10
Type of information: Co-promotion agreement
Compound: Grazax® (immunotherapy tablet)
Company: ALK Abello (Denmark) Merck MSD France (USA - France)
Therapeutic area: Respiratory diseases - Allergic diseases
Type agreement: co-promotion
Action mechanism: Grazax® is a fast-dissolving, once daily allergy immunotherapy tablet (AIT) for home treatment of grass pollen allergy. Grazax® works by inducing a protective immune response and offers patients sustained relief of their allergy symptoms.
Disease: grass pollen allergy
Details: ALK has announced that the company has entered into a co-promotion agreement with MSD (known as Merck inside the United States and Canada) for Grazax® in France, the second-largest allergy immunotherapy market in the world.
So far, 17 randomised, controlled clinical trials have been completed, and have delivered robust clinical evidence in significant favour of the treatment. Grazax® is currently available as a reimbursed treatment in 16 European countries. ALK's partner in North America, Merck, plans to file a New Drug Application for grass AIT with the FDA in 2013.
Financial terms: Under the agreement, ALK will book all sales of Grazax® and MSD will receive a co-promotion fee from ALK which reflects the product's overall sales performance in France. The agreement is expected to have a limited impact on ALK's financial outlook for 2012.
Latest news:
